The control subjects were tested only once. Neuropsychometric tests and the event-related potential, P300 were administered to the MS patients before corticosteroid treatment, and 3 months later. We enrolled 35 definite MS patients and 21 healthy subjects. In this study, we evaluated the cognitive status of MS patients during acute relapses. However, cognitive impairment may constitute an substantial part of a new relapse. The results obtained in the present study support the value of the MoCA test as a screening tool for the presence of cognitive dysfunction in MS patients, even in patients with mild functional disability (EDSS).ĭuring acute relapses of multiple sclerosis (MS), physical symptoms attract utmost care. In addition, there was no significant correlation between the MSNQ-P and the neuropsychological factors, whereas significant correlations were found between two of those factors (Learning and Delayed recall) and the MSNQ-I, suggesting that the informant version is more reliable than the patient version for the presence of cognitive deficits. the MoCA test was correlated with the MSNQ-I but only marginally with the MSNQ-P. There were significant correlations between the MoCA test and the three factors derived from the neuropsychological evaluation (Executive/speed of processing, Learning, Delayed recall). In addition to the MoCA, they were administered the MSNQ-P (patient version) and the MSNQ-I (informant version), the bDI-FS and a comprehensive neuropsychological test battery.

the objective of this study was to evaluate the clinical value of the Montreal Cognitive Assessment (MoCA) test in detecting cognitive deficits in MS patients.įorty-one (70.1% women, mean age 44.51 ☗.43) mildly impaired (EDSS: 2.26 ☑.87) MS patients were recruited for this study.

Since a large proportion of multiple sclerosis (MS) patients exhibit cognitive deficits, it is important to have reliable and cost-effective screening measures that can be used to follow patients effectively.

Moca test.pdf